Capmatinib, an oral adenosine triphosphate (ATP)-competitive MET inhibitor, demonstrated anti-cancer efficacy with an ORR of 68% and a median PFS of 9.69 months in treatment-naïve patients in the phase II GEOMETRY mono-1 trial (11). Here, MET is linked to cancer.